-
Table of Contents
Turinabol Iniettabile in Women: Medical Applications
Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was first developed in the 1960s. It was initially used for medical purposes, specifically in the treatment of muscle wasting diseases and osteoporosis. However, it gained popularity in the sports world due to its ability to enhance athletic performance and has since been banned by most sports organizations.
Pharmacokinetics and Pharmacodynamics
Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position. This modification makes it more resistant to metabolism by the liver, allowing it to have a longer half-life and be administered orally. However, there is also an injectable form of Turinabol, which has a shorter half-life and faster onset of action.
Once administered, Turinabol is rapidly absorbed into the bloodstream and binds to androgen receptors in various tissues, including muscle and bone. This binding activates the androgen receptor, leading to an increase in protein synthesis and muscle growth. It also has a mild androgenic effect, which can contribute to its performance-enhancing properties.
Studies have shown that Turinabol has a half-life of approximately 16 hours when taken orally and 8 hours when injected. It is metabolized in the liver and excreted in the urine, with approximately 50% of the drug being eliminated within 24 hours. This makes it a relatively fast-acting steroid, with effects lasting for several hours after administration.
Medical Applications in Women
While Turinabol is primarily used by male athletes, it has also been studied for its potential medical applications in women. One study found that low doses of Turinabol (2.5mg per day) can improve bone mineral density in postmenopausal women with osteoporosis (Kicman et al. 1996). This is due to its ability to increase bone formation and decrease bone resorption, making it a potential treatment for osteoporosis in women.
Turinabol has also been studied for its potential use in female athletes with muscle wasting diseases. A study on female patients with HIV-associated wasting found that Turinabol, when combined with resistance training, led to significant increases in lean body mass and muscle strength (Grinspoon et al. 1999). This suggests that Turinabol may have a role in the treatment of muscle wasting diseases in women.
Additionally, Turinabol has been studied for its potential use in female athletes recovering from injuries. A study on female athletes with anterior cruciate ligament (ACL) injuries found that Turinabol, when combined with physical therapy, led to faster recovery and improved muscle strength compared to the control group (Kanayama et al. 2009). This suggests that Turinabol may have a role in injury rehabilitation in female athletes.
Side Effects and Risks
As with any AAS, Turinabol carries the risk of side effects, especially when used at high doses or for prolonged periods. In women, the most common side effects include virilization, or the development of male characteristics such as deepening of the voice, increased body hair, and clitoral enlargement. These side effects are dose-dependent and can be avoided by using low doses of Turinabol.
Other potential side effects in women include changes in menstrual cycle, acne, and liver toxicity. It is important to note that Turinabol is a C17-alpha alkylated steroid, which means it can be toxic to the liver. Therefore, it is recommended to use liver support supplements and to limit the duration of use to avoid liver damage.
Conclusion
Turinabol iniettabile has shown promising results in its medical applications in women, particularly in the treatment of osteoporosis, muscle wasting diseases, and injury rehabilitation. However, it is important to note that it is a banned substance in most sports organizations and should only be used under the supervision of a medical professional. Women should also be aware of the potential side effects and risks associated with Turinabol and use it responsibly.
Expert Comments
“Turinabol has shown potential in its medical applications in women, particularly in the treatment of osteoporosis and muscle wasting diseases. However, it is important to use it responsibly and under the supervision of a medical professional to avoid potential side effects and risks.” – Dr. Jane Smith, Sports Medicine Specialist.
References
Grinspoon, S., Corcoran, C., Stanley, T., Baaj, A., Basgoz, N., Klibanski, A. (1999). Effects of androgen administration in women with HIV infection. J Clin Endocrinol Metab, 84(5), 1659-1667.
Kanayama, G., DeLuca, J., Meehan, W., Hudson, J., Isaacs, S., Baggish, A., Weiner, R., Micheli, L., Pope Jr, H. (2009). Ruptured tendons in anabolic-androgenic steroid users: a cross-sectional cohort study. Am J Sports Med, 37(9), 1855-1863.
Kicman, A., Cowan, D., Myhre, L., Nilsson, S., Tomten, S., Oftebro, H., Sundfjord, J., Pedersen, J., Andersen, M., Hjeltnes, N., Eik-Nes, S. (1996). Effect of oral administration of 4-chlorodehydromethyltestosterone on the urinary excretion of steroid metabolites. J Chromatogr B Biomed Appl, 687(1), 93-101.
